October 22, 2015.
A new alliance has launched to educate the public, policymakers and other key stakeholders about Risk Evaluation and Mitigation Strategies (REMS). The Patients Alliance for Drug Safety Protections is comprised of 20 public health, patient advocacy, health professional and disease organizations. To underscore the value of REMS to public health, the Alliance unveiled a new online resource, www.drugprotections.org that translates the latest facts about the REMS program in layman's terms. Designed for ease of use, the online hub summarizes the history and purpose of REMS, what REMS entails and the number of medicines now marketed with a REMS. In addition, the website provides links to information about REMS from FDA and other reputable source and will serve as a clearinghouse for the coalition's policy materials.
Read the full release.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.